Idebenone: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Use in Age-Related Cognitive Disorders

Drugs & Aging

Volumn 5, Issue 2, 1994, Pages 133-152

  Gillis, Jane C ^a   Benfield, Paul ^a   McTavish, Donna ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOQUINONE DERIVATIVE; IDEBENONE; OXIRACETAM; PSYCHOTROPIC AGENT; PYRROLIDINE DERIVATIVE;

AGING; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; HUMAN; INTESTINE ABSORPTION; MEMORY; METABOLISM; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; TISSUE DISTRIBUTION;

ADMINISTRATION, ORAL; AGING; BENZOQUINONES; COGNITION DISORDERS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INTESTINAL ABSORPTION; MEMORY; PSYCHOTROPIC DRUGS; PYRROLIDINES; RANDOMIZED CONTROLLED TRIALS; TISSUE DISTRIBUTION;

EID: 0028486222     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-199405020-00007     Document Type: Article

References (63)

1. Effects of idebenone (cv-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs
2. Inhibition of lipid peroxidation by a novel compound (cv-2619) in brain mitochondria and mode of action of the inhibition
3. ESR spin trapping studies on the OH· free radical reactions of idebenone
4. Oral administration of idebenone, a stimulator of NGF synthesis, recovers reduced ngf content in aged rat brain
5. Effect of cv-2619 (idebenone) on the half-life and hemolysis of red blood cells in stroke-prone spontaneously hypertensive rats (shrsp)
6. 2+ channels: effects of bifemelane and several nootropic agents
7. 2+ channels in cultured adrenal chromaffin cells
8. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line
9. Idebenone attenuates neuronal degeneration induced by intrastriatal injection of excitotoxins
10. Idebenone and vinpocetine augment long-term potentiation in hippocampal slices of the guinea-pig
11. Idebenone improves learning and memory impairment induced by cholinergic or serotonergic dysfunction in rats
12. Beneficial effect of idebenone (cv-2619) on cerebral ischemia-induced amnesia in rats
13. Effects of idebenone on memory impairment induced in ischemic and embolization models of cerebrovascular disturbance in rats
14. A comparative study of idebenone and bifemelane; using clinical neurophysiological methods in normal volunteers and inpatients with cerebrovascular dementia
15. Effects of idebenone on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia
16. Brain distribution of idebenone and its effect on local cerebral glucose utilization in rats
17. Stimulation of the respiratory and phosphorylating activities in rat brain mitochondria by idebenone (cv-2619), a new agent improving cerebral metabolism
18. Nootropic candidates inhibit head-twitches induced by mescaline in mice
19. Effects of idebenone on monoamine metabolites in cerebrospinal fluid of patients with cerebrovascular dementia
20. Therapeutic frontiers in Alzheimer’s disease
21. A proposal for reconsideration of the role of oxygen free radicals in cell differentiation and aging
22. The role of glutamate in neurotransmission and in neurologic disease
23. Potential therapeutic strategies for cognitive disorders
24. Chemistry, toxicology, pharmacology and pharmacokinetics of idebenone: a review
25. Therapeutic strategies in dementia disorders
26. Organic brain syndromes, Alzheimer type
27. Diagnostic and pharmacological approaches in Alzheimer’s disease
28. Effects of putative cognitive function-enhancing drugs and dopaminergic agents on somatostatin and neuropeptide y in rat brain
29. Comparison of the effects of bifemelane hydrochloride, idebenone and indeloxazine hydrochloride on ischemia-induced depletion of brain acetylcholine levels in gerbils
30. Acetylcholine and choline levels in post-mortem human brain tissue: preliminary observations in Alzheimer’s disease
31. Glucose metabolism and acetylcholine synthesis in relation to neuronal activity in Alzheimer’s disease
32. l4C]catecholamine formation by cultured bovine adrenal chromaffin cells
33. Roles of metabotropic and ionotropic glutamate receptors in the long-term potentiation of hippocampal mossy fiber synapses
34. Idebenone and vinpocetine augment long-term potentiation in hippocampal slices on the guinea pig
35. Taking stock of cognition enhancers
36. Steady-state pharmacokinetics of idebenone in healthy volunteers
37. Clinical phase I study of idebenone (cv-2619)
38. Steady-state pharmacokinetics of idebenone in patients with moderate renal impairment
39. Steady state pharmacokinetics of idebenone in patients with moderate hepatic impairment
40. An investigation into the pharmacokinetics of repetitive administration of cv-2619 tablets in treatment of geriatric patients with cerebrovascular disorders
41. An investigation of the pharmacokinetics of cv-2619 (idebenone) tablets in patients with cerebrovascular disorders
42. An early phase I study to determine the tolerance, safety and pharmacokinetics of idebenone following multiple doses
43. Disposition of idebenone (cv-2619), a new cerebral metabolism improving agent, in rats and dogs
44. Evaluation of the clinical efficacy of idebenone in patients affected by chronic cerebrovascular disorders
45. Acute confusional states, amnesia, and dementia
46. Proof of efficacy of nootropics for the indication “dementia” (phase III) — recommendations
47. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in Alzheimer’s disease
48. Utility of long-term administration of cv-2619 (idebenone) in patients with cerebrovascular disorder
49. A long-term trial of idebenone in cerebrovascular diseases
50. Efficacy and safety of cv-2619 tablets in long-term clinical treatment of elderly cerebral arteriosclerotic patients
51. Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly
52. Effects of idebenone on quality of life of patients with cerebrovascular disease
53. Double-blind study to compare two dose regimes of idebenone in the treatment of patients with cognitive deficit associated with cerebrovascular disease
54. Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial
55. Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia
56. Idebenone in senile dementia of alzheimer type: a multicentre study
57. Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial
58. Clinical utility of ct-848 (oxiracetam) in the treatment of cerebral infarction — a multi-center, double-blind study in comparison with idebenone
59. Clinical evaluation of web 1881 (nebracetam fumarate) in patients with cerebrovascular disorders — a double blind study in comparison with idebenone
60. Psychostimulants, analeptics, nootropics: an attempt to differentiate and assess drugs designed for the treatment of impaired brain functions
61. Prevalence of Alzheimer’s disease in a community population of older persons
62. The role of cholinesterase inhibitors in Alzheimer’s disease